2023
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi S, Riaz I, He H, Imran M, Orme J, Childs D, Ravi P, Hussain S, Singh P, Bryce A. The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. Journal Of Clinical Oncology 2023, 41: 5088-5088. DOI: 10.1200/jco.2023.41.16_suppl.5088.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerVolume of diseaseTriplet therapyDoublet therapyLV diseaseHazard ratioCastration-sensitive prostate cancerSensitive prostate cancerLow-volume diseaseEfficacious treatment optionConfidence intervalsInverse variance approachMixed treatment comparisonMCSPC patientsTreatment intensificationTreatment optionsClinical trialsProstate cancerEfficacious treatmentTreatment selectionDisease subgroupsPatientsComparative effectivenessTherapyDiseaseA living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).
Bin Riaz I, Naqvi S, He H, Siddiqi R, Asghar N, Ravi P, Hussain S, Singh P, Bryce A. A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC). Journal Of Clinical Oncology 2023, 41: 193-193. DOI: 10.1200/jco.2023.41.6_suppl.193.Peer-Reviewed Original ResearchProgression-free survivalMetastatic castration-sensitive prostate cancerAndrogen pathway inhibitorsMCSPC patientsTriplet regimensHazard ratioSignificant improved progression-free survivalCastration-sensitive prostate cancerImproved progression-free survivalSubgroup dataOverall patient populationTiming of metastasisConfidence intervalsVolume of diseaseMixed treatment comparisonEvidence synthesis frameworkSTAMPEDE trialTreatment intensificationTriplet regimenDisease volumeMetastatic presentationSystemic therapyOptimal therapyRandomized comparisonPatient populationAdjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Sipra Q, Bin Riaz I, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA). Journal Of Clinical Oncology 2023, 41: 694-694. DOI: 10.1200/jco.2023.41.6_suppl.694.Peer-Reviewed Original ResearchRenal cell carcinomaDisease-free survivalAdjuvant immunotherapyBaseline riskCell carcinomaTreatment optionsImproved disease-free survivalLocalized Renal Cell CarcinomaRisk categoriesAdjuvant treatment optionsAbsolute risk differenceUnique treatment optionRisk stratification systemMixed treatment comparisonSignificant differencesRelative effect estimatesEvidence synthesis frameworkAdjuvant pembrolizumabNivolumab-ipilimumabOverall survivalTreatment landscapeAbsolute benefitPreferred treatmentRecent trialsDisease progressionReal-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity
2022
1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review
Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Khakwani K, Liu H, Hussain S, Singh P, Murad M, Bryce A. 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. Annals Of Oncology 2022, 33: s1193. DOI: 10.1016/j.annonc.2022.07.1903.Peer-Reviewed Original ResearchTreatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
Sipra Q, Bin Riaz I, Naqvi S, He H, Liu H, Bryce A, Murad M, McBane R. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis. Journal Of Clinical Oncology 2022, 40: e24070-e24070. DOI: 10.1200/jco.2022.40.16_suppl.e24070.Peer-Reviewed Original ResearchNet clinical benefitMixed treatment comparisonMajor bleedingClinical benefitSystematic reviewCANVAS trialOdds ratioGreater net clinical benefitRelevant non-major bleedingSignificant differencesTreatment comparisonsEffect estimatesEfficacy of DOACsNon-major bleedingVTE risk reductionVenous thromboembolism recurrenceCumulative ranking curvePatient-important outcomesConfidence intervalsMantel-Haenszel methodTreatment of catsFixed-effects modelThromboembolism recurrenceVTE recurrenceCause mortality
2021
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-Analysis